ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Ensysce Biosciences Inc

Ensysce Biosciences Inc (ENSC)

2.15
0.08
(3.86%)
2.15
0.00
( 0.00% )

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
2.15
Bid
2.08
Ask
2.14
Volume
48,673
2.06 Day's Range 2.15
1.62 52 Week Range 14.67
Market Cap
Previous Close
2.07
Open
2.15
Last Trade
2
@
2.1386
Last Trade Time
18:06:16
Financial Volume
$ 103,222
VWAP
2.1207
Average Volume (3m)
1,861,993
Shares Outstanding
2,370,698
Dividend Yield
-
PE Ratio
-3.98
Earnings Per Share (EPS)
-3.37
Revenue
5.21M
Net Profit
-7.99M

About Ensysce Biosciences Inc

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Ensysce's products are anticipated to provid... Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Ensysce's products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. Show more

Sector
Blank Checks
Industry
Pharmaceutical Preparations
Headquarters
New York, New York, USA
Founded
2017
Ensysce Biosciences Inc is listed in the Blank Checks sector of the NASDAQ with ticker ENSC. The last closing price for Ensysce Biosciences was $2.07. Over the last year, Ensysce Biosciences shares have traded in a share price range of $ 1.62 to $ 14.67.

Ensysce Biosciences currently has 2,370,698 shares outstanding. The market capitalization of Ensysce Biosciences is $4.91 million. Ensysce Biosciences has a price to earnings ratio (PE ratio) of -3.98.

ENSC Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.27-11.15702479342.422.46991.991097112.09814854CS
4-0.11-4.867256637172.262.62991.992578302.34114924CS
12-1.29-37.53.444.851.6218619933.47536402CS
26-3.59-62.5435540075.7410.961.629189883.61788885CS
52-5.7205-72.68280287157.870514.671.6277070848.49132642CS
156-1617.85-99.8672839506162033121.623301474138.37632418CS
260-57381.85-99.99625331157384616321.6231624142957.96619067CS

ENSC - Frequently Asked Questions (FAQ)

What is the current Ensysce Biosciences share price?
The current share price of Ensysce Biosciences is $ 2.15
How many Ensysce Biosciences shares are in issue?
Ensysce Biosciences has 2,370,698 shares in issue
What is the market cap of Ensysce Biosciences?
The market capitalisation of Ensysce Biosciences is USD 4.91M
What is the 1 year trading range for Ensysce Biosciences share price?
Ensysce Biosciences has traded in the range of $ 1.62 to $ 14.67 during the past year
What is the PE ratio of Ensysce Biosciences?
The price to earnings ratio of Ensysce Biosciences is -3.98
What is the cash to sales ratio of Ensysce Biosciences?
The cash to sales ratio of Ensysce Biosciences is 6.1
What is the reporting currency for Ensysce Biosciences?
Ensysce Biosciences reports financial results in USD
What is the latest annual turnover for Ensysce Biosciences?
The latest annual turnover of Ensysce Biosciences is USD 5.21M
What is the latest annual profit for Ensysce Biosciences?
The latest annual profit of Ensysce Biosciences is USD -7.99M
What is the registered address of Ensysce Biosciences?
The registered address for Ensysce Biosciences is 250 WEST 57TH STREET, SUITE 2223, NEW YORK, NEW YORK, 10107
What is the Ensysce Biosciences website address?
The website address for Ensysce Biosciences is www.leisureacq.com
Which industry sector does Ensysce Biosciences operate in?
Ensysce Biosciences operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
JZJianzhi Education Technology Group Company Ltd
$ 5.30
(85.31%)
2.93M
SLRXSalarius Pharmaceuticals Inc
$ 1.02
(63.17%)
10.45M
RELIReliance Global Group Inc
$ 1.82
(54.24%)
3.01M
INEOINNEOVA Holdings Ltd
$ 1.5798
(42.32%)
4.09M
RGCRegencell Bioscience Holdings Ltd
$ 79.00
(31.67%)
346.14k
RUNSunrun Inc
$ 7.00
(-27.39%)
3.87M
SEDGSolarEdge Technologies Inc
$ 18.81
(-21.56%)
639.89k
CDTGCDT Environmental Technology Investment Holdings Ltd
$ 1.12
(-18.33%)
242.47k
ENPHEnphase Energy Inc
$ 38.60
(-15.96%)
728.54k
DWSNDawson Geophysical Company
$ 2.51
(-13.45%)
3.64M
GNLNGreenlane Holdings Inc
$ 0.0117
(-5.65%)
45.17M
GTIGraphjet Technology
$ 0.0798
(4.18%)
38.51M
HCTIHealthcare Triangle Inc
$ 0.02545
(-3.60%)
32.05M
SLRXSalarius Pharmaceuticals Inc
$ 1.02
(63.17%)
10.45M
TDTHTrident Digital Tech Holdings Ltd
$ 0.295
(20.65%)
8.83M

ENSC Discussion

View Posts
Muhbruh Muhbruh 1 month ago
$ENSC Ensysce Biosciences Q1 EPS $(1.39) Beats $(3.02) Estimate, Sales $1.32M Up From $305.72K YoY
👍️ 1
Monksdream Monksdream 1 month ago
ENSC reports Monday May 12 according to Seeking Alpha
๐Ÿ‘๏ธ0
BeeHaus2 BeeHaus2 1 month ago
If they execute properly $ENSC is a steal at $2 IMO
๐Ÿ‘๏ธ0
Monksdream Monksdream 2 months ago
ENSC under $4
๐Ÿ‘๏ธ0
BeeHaus2 BeeHaus2 2 months ago
Ensysce Biosciences, Inc (NASDAQ:ENSC) stock gained almost 100% with a strong session volume compared to the average volume of 81.23K, as per data from Benzinga Pro.

Ensysce Biosciences on Wednesday 4/23 received a Notice of Allowance from the U.S. Patent and Trademark Office for the issuance of a patent entitled Enzyme-Cleavable Methadone Prodrugs and Methods of Use Thereof including both composition of matter and method of use claims.PF9001, the medication covered by this patent, is designed to provide a safer treatment option for opioid use disorder (OUD) by using Ensysceโ€™s TAAP and MPAR abuse-deterrent and overdose protection technologies.
๐Ÿ‘๏ธ0
StockFOXXX StockFOXXX 2 months ago
Nope. They're still firmly in control 
👍️ 1
BeeHaus2 BeeHaus2 2 months ago
Volume is off the charts!
๐Ÿ‘๏ธ0
BeeHaus2 BeeHaus2 2 months ago
Nice pm move. I dont see any news so probably a nice short squeeze here. The shorts have controlled the trading here for a long time so hopefully this is the beginning of a change in long term direction.
๐Ÿ‘๏ธ0
glenn1919 glenn1919 2 months ago
ensc.............................................................p/m
๐Ÿ‘๏ธ0
Monksdream Monksdream 2 months ago
ENSC, new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 2 months ago
ENSC, new 52 week low
๐Ÿ‘๏ธ0
glenn1919 glenn1919 2 months ago
ENSC.................................https://stockcharts.com/h-sc/ui?s=ENSC&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
Shift-4 Shift-4 5 months ago
Awesome news, don't be fooled by the MM tree shake after the nice premarket spike; good times are starting.

-$
๐Ÿ‘๏ธ0
BeeHaus2 BeeHaus2 5 months ago
https://ir.ensysce.com/news/press-releases/detail/180/ensysce-biosciences-announces-positive-interim-data-for
๐Ÿ‘๏ธ0
BeeHaus2 BeeHaus2 5 months ago
The good news we were anticipating.
๐Ÿ‘๏ธ0
BeeHaus2 BeeHaus2 5 months ago
https://finance.yahoo.com/news/ensc-continues-announce-potential-life-110600665.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuYmluZy5jb20v&guce_referrer_sig=AQAAAFtsmNC-EByKeQlVf7gg4DtBG1cmHV_YM3Y2nOqgEJ0TXStxvWdaennPH-WNC9uVGerYHWpmdvpEG6xQyMhFc80p_gYO_JjquKHxxV6mmxdVZ2U8cDGkDtqvIas0ooQhcy4KUCIA14ehuBib-oC4d6K61_oUPR6291lpXxiwNst5
๐Ÿ‘๏ธ0
BeeHaus2 BeeHaus2 5 months ago
Looking forward to a productive 2025
๐Ÿ‘๏ธ0
BeeHaus2 BeeHaus2 5 months ago
https://finance.yahoo.com/news/ensysce-biosciences-issues-annual-shareholder-130000054.html
๐Ÿ‘๏ธ0
BeeHaus2 BeeHaus2 6 months ago
Boom! Lets go!
๐Ÿ‘๏ธ0
BeeHaus2 BeeHaus2 6 months ago
Hey Glenn - when you send charts can you give sentiment? Good or Bad?
๐Ÿ‘๏ธ0
glenn1919 glenn1919 6 months ago
ENSC.....................https://stockcharts.com/h-sc/ui?s=ENSC&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
BeeHaus2 BeeHaus2 6 months ago
Interesting that this is holding up nicely after RS. I'm still bullish long term
๐Ÿ‘๏ธ0
BeeHaus2 BeeHaus2 6 months ago
And there it is. RS 1-15
https://ih.advfn.com/stock-market/NASDAQ/ensysce-biosciences-ENSC/stock-news/95028942/form-8-k-current-report
one-for-fifteen (1-for-15) reverse stock split (the โ€œReverse Stock Splitโ€) of our common stock, par value $0.0001 (the โ€œCommon Stockโ€). The Reverse Stock Split will be effective as of 12:01 am on December 6, 2024 (the โ€œEffective Timeโ€).
๐Ÿ‘๏ธ0
BeeHaus2 BeeHaus2 7 months ago
RS coming. Not happy.

The stockholders approved an amendment to the Companyโ€™s Certificate of Incorporation to authorize the Companyโ€™s Board of Directors to combine outstanding shares of the Companyโ€™s common stock into a lesser number of outstanding shares, a โ€œReverse Stock Split,โ€ by a ratio of not less than one-for-ten and not more than one-for-forty, with the exact ratio to be set within this range by the Board in its sole discretion:
๐Ÿ‘๏ธ0
BeeHaus2 BeeHaus2 7 months ago
TIme to climb back up in line with the 5yr chart.
LFG!
๐Ÿ‘๏ธ0
Shift-4 Shift-4 7 months ago
ENSC profile via Zacks --> Yahoo:

https://finance.yahoo.com/news/ensc-improves-position-100000760.html

"We encourage investors to take a look at ENSC and consider the stock before the anticipated positive testing results come in."

-$
👍️ 1 🤑 1
glenn1919 glenn1919 7 months ago
ensc............................https://stockcharts.com/h-sc/ui?s=ensc&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
Helter Skelter Helter Skelter 7 months ago
As of November 11, 2024, the registrant had 19,574,014 shares of common stock, $0.0001 par value per share, outstanding.

I'll get you an estimate on the float in a little bit...they turned a nice profit in the Q thanks to a gov grant...counted as revenue...

$ENSC
๐Ÿ‘๏ธ0
Shift-4 Shift-4 7 months ago
Itโ€™s nonsense. Iโ€™ll give it to the guy, heโ€™s a good scalper and can hit tops on technical moves. But fundamentalsโ€ฆnot so much.

There is no dilution because the warrants have been transferred (mostly from sabby) to a new owner who wants to convert them, but they are tied up until the shareholder meeting to vote on full conversion.

Weโ€™re seeing the effects of a chronically depressed market cap, bullish investors suddenly holding the warrants, and the loss of downward pressure due to the near-unlimited shorting collateral those warrants represented to Sabby. But dilution? Nope. Thereโ€™s nothing available to dilute with.

-$
๐Ÿ‘๏ธ0
madras50 madras50 7 months ago
geez man you said that about WBUY and it nothing but go up.
๐Ÿ‘๏ธ0
BeeHaus2 BeeHaus2 7 months ago
Anyone know how many shares available, outstanding, float? I'm seeing conflicting info
๐Ÿ‘๏ธ0
glenn1919 glenn1919 7 months ago
ENSC..........................................https://stockcharts.com/h-sc/ui?s=ENSC&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 7 months ago
ENSC: Nice DD --- THANKS!!
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 7 months ago
Then try McDonald's new "E-Coli UN-Happy Meal" for breakfast, Homeboy!!
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 7 months ago
DILUTING THE SNOT OUT OF THIS...
๐Ÿ‘๏ธ0
tw0122 tw0122 7 months ago
Phase 3 late 2025...
Ensysce Biosciences submits Phase 3 study protocol for pain treatmentPublished 09/19/2024, 07:12 AM


Ensysce Biosciences submits Phase 3 study protocol for pain treatment


ENSC5.42%

SAN DIEGO - Ensysce Biosciences Inc. (NASDAQ:ENSC) has submitted a protocol for a Phase 3 clinical trial to the FDA, aiming to evaluate the efficacy and safety of its drug candidate PF614 for treating moderate to severe pain after abdominoplasty. The study will compare the analgesic efficacy of PF614 against a placebo and an active comparator at several clinical sites in the United States.
The trial, which is expected to yield results in late 2025, is part of the company's efforts to introduce PF614 as a potential improvement over existing oxycodone products. Ensysce's Chief Medical Officer, Dr. Bill Schmidt, expressed optimism that the trial will reinforce PF614's positive attributes. CEO Dr. Lynn Kirkpatrick highlighted the drug's extended duration, which could address the issue of breakthrough pain between doses, and its reduced potential for abuse.
Ensysce Biosciences focuses on developing prescription drugs with enhanced safety profiles, leveraging its proprietary Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms. The company aims to offer safer treatment options for severe pain and contribute to reducing medication abuse-related deaths.
The forward-looking statements in the original press release underscore the uncertainties inherent in the drug development process, including the possibility of encountering delays or failing to demonstrate safety and efficacy. The company acknowledges the risks and emphasizes that its product candidates are still in clinical stages and not yet approved for commercialization.
This news is based on a press release statement from Ensysce Biosciences.
In other recent news, Ensysce Biosciences has secured approximately $5 million from stock sales, managed by H.C. Wainwright & Co. The funds are anticipated to be allocated towards the continued development of its TAAP™ and MPAR® programs. Concurrently, the company has received a $14 million grant from the National Institutes of Health for the further development of its opioid product, PF614-MPAR. The funding will support the Phase 1b clinical trial of this opioid, designed to deter abuse and prevent overdose.
๐Ÿ‘๏ธ0
tw0122 tw0122 7 months ago
Loosing some sizzle from hot frying pan . Well done to medium rare
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 7 months ago
ENSC: Below is what "COPILOT" had to say about this right now, in the late Post-Market:

"Why is ENSC stock up 48% in the Post-Market today?
It looks like Ensysce Biosciences Inc. (ENSC) has seen a significant surge in their stock price due to a $5 million concurrent registered direct offering and exercise of warrants. This move has likely attracted investor interest, contributing to the 48% rise in the post-market."
๐Ÿ‘๏ธ0
Shift-4 Shift-4 7 months ago
Up 60% in AH to new highs due to recent 13G disclosing 9.9% investment (1.475m shares) by RA Capital.

Add this to the 1.3m from Perceptive Advisors on 10/29/24, and we've added 2.775m in institutional buys in the past 8 days.

Cost to borrow is obscene, and the market is *hot* right now. We could moon tomorrow.

-$
๐Ÿ‘๏ธ0
tw0122 tw0122 7 months ago
 14.4 million shares each with an exercise price of $0.47 per share, while up to 752,969 shares are issuable under the placement warrants, according to the filing.
๐Ÿ‘๏ธ0
Shift-4 Shift-4 7 months ago
They were paying me 385% at one point (not recently).

I'm here for the squeeze.

-$
๐Ÿ‘๏ธ0
BeeHaus2 BeeHaus2 7 months ago
Another solid day on good volume. Need to get through the .80s and test 1.00 next week.
๐Ÿ‘๏ธ0
glenn1919 glenn1919 7 months ago
ENSC............................................https://stockcharts.com/h-sc/ui?s=ENSC&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
INV4 INV4 7 months ago
ENSC looking good 😃

GLTA $ENSC
๐Ÿ‘๏ธ0
shrinknp shrinknp 7 months ago
The interest rate for ENSC loaned securities is 104%. Can someone explain to me the ludicrousness of this?
๐Ÿ‘๏ธ0
BeeHaus2 BeeHaus2 7 months ago
Time for the move above $1
👍️ 1 🚀 1
INV4 INV4 8 months ago
Bought some ENSC this morning!

$ENSC
๐Ÿ‘๏ธ0
madras50 madras50 8 months ago
somehow i doubt that
๐Ÿ‘๏ธ0
PirateLeviathan8 PirateLeviathan8 8 months ago
ENSC the next DRUG
๐Ÿ‘๏ธ0
PirateLeviathan8 PirateLeviathan8 8 months ago
ENSC go to the moon
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock